Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: Evidence from meta-analysis of 18 studies

Diabetes Care

Volumn 35, Issue 6, 2012, Pages 1388-1393

  Zhang, Hui ^a,b   Mohan, Viswanathan ^d,e   Zhu, Shimiao ^b,c   Venkatesan, Radha ^d,e   Chen, Jing ^c   Wang, Jianmin ^c   Tang, Yang ^c   Chen, Haiping ^a   Hu, Hailong ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CANGZHOU CENTRAL HOSPITAL   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d MADRAS DIABETES RESEARCH FOUNDATION   (India)

^e WHO Collaborating Centre for Non Communicable Diseases Prevention and Control   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ALBUMIN EXCRETION RATE; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; ASIAN; CAUCASIAN; CODON; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE DURATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA POLYMORPHISM; ETHNIC DIFFERENCE; ETHNICITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; KIDNEY FAILURE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA GENE; RECEPTOR GENE; RELIABILITY; RENAL SYSTEM PARAMETERS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

ALANINE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; PROLINE;

EID: 84861777860     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-2142     Document Type: Article

References (39)

1. Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2006 Annual Data Report. Am J Kidney Dis 2007;49:A6-A7, S1-S296
2. Rychlík I, Miltenberger-Miltenyi G, Ritz E. The drama of the continuous increase in end-stage renal failure in patients with type II diabetes mellitus. Nephrol Dial Transplant 1998;13(Suppl. 8):6-10 (Pubitemid 28532587)
3. Lu B, Wen J, Song XY, et al. High prevalence of albuminuria in population-based patients diagnosed with type 2 diabetes in the Shanghai downtown. Diabetes Res Clin Pract 2007;75:184-192 (Pubitemid 44894601)
4. Scazzocchio B, Varì R, Filesi C, et al. Cyanidin-3-O-β- glucoside and protocatechuic acid exert insulin-like effects by upregulating PPARγ activity in human omental adipocytes. Diabetes 2011;60:2234-2244
5. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower bodymass index and improved insulin sensitivity. Nat Genet 1998;20:284-287 (Pubitemid 28507675)
6. Liu L, Zheng T, Wang F, et al. Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Care 2010;33:144-149
7. De Cosmo S, Motterlini N, Prudente S, et al.; BENEDICT Study Group. Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT. Diabetes 2009;58:2920-2929
8. Wu LS, Hsieh CH, Pei D, Hung YJ, Kuo SW, Lin E. Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol Dial Transplant 2009;24:3360-3366
9. Mori H, Ikegami H, Kawaguchi Y, et al. The Pro12 → Ala substitution in PPARgamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001;50:891-894 (Pubitemid 32242650)
10. De Cosmo S, Prudente S, Lamacchia O, et al. PPAR{gamma}2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies. Nephrol Dial Transplant 2011;26:4011-4016.
11. Gayathri SB, Radha V, Vimaleswaran KS, Mohan V. Association of the PPARGC1A gene polymorphism with diabetic nephropathy in an Asian Indian population (CURES-41). Metab Syndr Relat Disord 2010;8:119-126
12. Radha V, Vimaleswaran KS, Babu HN, et al. Role of genetic polymorphism peroxisome proliferator-activated receptor-gamma2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects: Evidence for heterogeneity. Diabetes Care 2006;29:1046-1051 (Pubitemid 44115242)
13. Handoll HH. Systematic reviews on rehabilitation interventions. Arch Phys Med Rehabil 2006;87:875 (Pubitemid 43767714)
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560 (Pubitemid 37088507)
15. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-1101
16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634 (Pubitemid 27387172)
17. Zhu S, Zhang H, Tang Y, Liu P, Wang J. DNMT3B polymorphisms and cancer risk: a meta analysis of 24 case-control studies. Mol Biol Rep 2012;39:4429-4437
18. Zhu W, Ji Y, Bu L, Yang Q. The correlativity study of peroxisome proliferator activated receptor γ2 gene polymorphism with susceptibility of diabetic nephropathy in type 2 diabetes mellitus. J Radioimmunology 2011;24:296-298
19. Lapice E, Pinelli M, Riccardi G, Vaccaro O. Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients: comment on the study by Liu et al. Diabetes Care 2010;33:e114
20. Wei F, Wang J, Wang C, Huo X, Xue Y, Bai L. The relationship between the pro12Ala polymorphism in PPAR-γ2 gene and diabetic nephropathy in Baotou. Chinese J Diabetes 2008;16:679-680
21. Li L, Liu L, Zheng T, Wang N, Wang F. Peroxisome proliferator activated receptor γ2 gene P12A polymorphism and type 2 diabetic nephropathy in Han population in Shanghai. J Shanghai Jiaotong Univ 2008;28:376-379
22. Erdogan M, Karadeniz M, Eroglu Z, Tezcanli B, Selvi N, Yilmaz C. The relationship of the peroxisome proliferator-activated receptor-gamma 2 exon 2 and exon 6 gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy. Diabetes Res Clin Pract 2007;78:355-359 (Pubitemid 350030322)
23. Pollex RL, Mamakeesick M, Zinman B, Harris SB, Hegele RA, Hanley AJ. Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. J Diabetes Complications 2007;21:166-171 (Pubitemid 46687068)
24. Maeda A, Gohda T, Funabiki K, Horikoshi S, Tomino Y. Peroxisome proliferator-activated receptor gamma gene polymorphism is associated with serum triglyceride levels and body mass index in Japanese type 2 diabetic patients. J Clin Lab Anal 2004;18:317-321 (Pubitemid 39577887)
25. Wu S. Study on the Relationship of Polymorphism of PPAR-γ2 and Type 2 Diabetes and Diabetic Nephropathy. Tianjin, Tianjin Medical University, 2004
26. Caramori ML, Canani LH, Costa LA, Gross JL. The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 2003;52:3010-3013 (Pubitemid 37466874)
27. Herrmann SM, Ringel J, Wang JG, Staessen JA, Brand E; Berlin Diabetes Mellitus (BeDiaM) Study. Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes 2002;51:2653-2657 (Pubitemid 34827420)
28. Tönjes A, Scholz M, Loeffler M, Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 2006;29:2489-2497 (Pubitemid 44912258)
29. Ochoa MC, Marti A, Azcona C, et al.; Groupo de Estudio Navarro de Obesidad Infantil (GENOI). Gene-gene interaction between PPAR gamma 2 and ADR beta 3 increases obesity risk in children and adolescents. Int J Obes Relat Metab Disord 2004;28(Suppl. 3):S37-S41
30. Ritz E, Rychlík I, Locatelli F, Halimi S. Endstage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;34:795-808 (Pubitemid 29521694)
31. Chantrel F, Enache I, Bouiller M, et al. Abysmal prognosis of patients with type 2 diabetes entering dialysis. Nephrol Dial Transplant 1999;14:129-136 (Pubitemid 29041882)
32. Hsueh WA, Bruemmer D. Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension 2004;43:297-305 (Pubitemid 38174129)
33. Duan SZ, Ivashchenko CY, Whitesall SE, et al. Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality. J Clin Invest 2007;117:812-822 (Pubitemid 46348540)
34. Gray SL, Dalla Nora E, Vidal-Puig AJ. Mouse models of PPAR-gamma deficiency: dissecting PPAR-gamma's role inmetabolic homoeostasis. Biochem Soc Trans 2005;33:1053-1058 (Pubitemid 41659112)
35. Chen J, Gu D, Chen CS, et al. Association between themetabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant 2007;22:1100-1106 (Pubitemid 46523424)
36. LeBrasseur NK, Kelly M, Tsao TS, et al. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab 2006;291:E175-E181 (Pubitemid 44035323)
37. Nawrocki AR, Rajala MW, Tomas E, et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferatoractivated receptor gamma agonists. J Biol Chem 2006;281:2654-2660 (Pubitemid 43845727)
38. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-1295 (Pubitemid 35373562)
39. Cabezas F, Lagos J, Céspedes C, Vio CP, Bronfman M, Marzolo MP. Megalin/LRP2 expression is induced by peroxisome proliferator-activated receptor -alpha and -gamma: implications for PPARs' roles in renal function. PLoS ONE 2011;6:e16794